Fig. 4From: Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trialsProportion of patients achieving complete asthma control with mepolizumab versus placebo. Complete asthma control was defined as an ACQ-5 score < 0.75. *Defined as an ACQ-5 score ≥ 1.5; †defined as an ACQ-5 score < 1.5. ACQ Asthma Control Questionnaire, CI confidence intervalBack to article page